Human Papilloma Virus (HPV) Market - Forecasts from 2019 to 2024
The global Human Papilloma Virus (HPV) Vaccine market is expected to grow at a CAGR of 9.79% during the forecast period to reach a total market size of US$5.790 billion by 2024, increasing from US$3.305 billion in 2018. According to the WHO guidelines, routine vaccination is recommended to all countries along with other vaccinations. Human Papilloma Virus (HPV) Vaccine protects from certain types of Human Papilloma Viruses that can lead to cancer or genital warts. According to the WHO guidelines, routine vaccination is recommended to all countries along with other vaccinations. These vaccines are on the “World Health Organisation’s list of Essential Medicines” and are considered as safe and effective medicines.
The market for global Human Papilloma Virus (HPV) Vaccine is augmented by increasing number of Cervical Cancer cases worldwide. Rising awareness regarding cervical cancer and HPV owing to the number of initiatives by the governments will also boost the market for the HPV vaccines. However, strict regulatory approval process for the vaccines might restrain the growth of the market during the given time frame.
The Global Human Papilloma Virus (HPV) Vaccine Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by type, indication, gender, and geography.
Based on type, the market has been segmented into quadrivalent HPV vaccine and bivalent HPV vaccine. On the basis of indication, the market is divided into cervical cancer, anal cancer, vaginal cancer, vulvar cancer, mouth cancer, and genital warts. The market is divided into males and females on the bases of gender.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the human papilloma virus (HPV) Vaccine market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the human papilloma virus (HPV) Vaccine market.
Segmentation:
The market for global Human Papilloma Virus (HPV) Vaccine is augmented by increasing number of Cervical Cancer cases worldwide. Rising awareness regarding cervical cancer and HPV owing to the number of initiatives by the governments will also boost the market for the HPV vaccines. However, strict regulatory approval process for the vaccines might restrain the growth of the market during the given time frame.
The Global Human Papilloma Virus (HPV) Vaccine Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by type, indication, gender, and geography.
Based on type, the market has been segmented into quadrivalent HPV vaccine and bivalent HPV vaccine. On the basis of indication, the market is divided into cervical cancer, anal cancer, vaginal cancer, vulvar cancer, mouth cancer, and genital warts. The market is divided into males and females on the bases of gender.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the human papilloma virus (HPV) Vaccine market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the human papilloma virus (HPV) Vaccine market.
Segmentation:
- By Type
- Quadrivalent HPV Vaccine
- Bivalent HPV Vaccine
- By Indication
- Cervical Cancer
- Anal Cancer
- Vaginal Cancer
- Vulvar Cancer
- Mouth Cancer
- Genital Warts
- By Gender
- Male
- Female
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- Italy
- Spain
- Others
- Middle East and Africa (MEA)
- Israel
- Saudi Arabia
- Others
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODO LOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY TYPE
5.1. Quadrivalent HPV Vaccine
5.2. Bivalent HPV Vaccine
6. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY INDICATION
6.1. Cervical Cancer
6.2. Anal Cancer
6.3. Vaginal Cancer
6.4. Vulvar Cancer
6.5. Mouth Cancer
6.6. Genital Warts
7. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY GENDER
7.1. Male
7.2. Female
8. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. UK
8.3.2. Germany
8.3.3. Italy
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Israel
8.4.2. Saudi Arabia
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Merck & Co Inc.
10.2. GlaxoSmithKline plc
10.3. Sanofi S.A.
10.4. Janssen Pharmaceuticals, Inc.
10.5. Inovio Pharmaceuticals Inc.
10.6. Pfizer Inc.
10.7. EyeGene Inc.
List of Figures
List of Tables
Disclaimer
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODO LOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY TYPE
5.1. Quadrivalent HPV Vaccine
5.2. Bivalent HPV Vaccine
6. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY INDICATION
6.1. Cervical Cancer
6.2. Anal Cancer
6.3. Vaginal Cancer
6.4. Vulvar Cancer
6.5. Mouth Cancer
6.6. Genital Warts
7. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY GENDER
7.1. Male
7.2. Female
8. HUMAN PAPILLOMA VIRUS (HPV) VACCINE MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. UK
8.3.2. Germany
8.3.3. Italy
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Israel
8.4.2. Saudi Arabia
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Australia
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Merck & Co Inc.
10.2. GlaxoSmithKline plc
10.3. Sanofi S.A.
10.4. Janssen Pharmaceuticals, Inc.
10.5. Inovio Pharmaceuticals Inc.
10.6. Pfizer Inc.
10.7. EyeGene Inc.
List of Figures
List of Tables
Disclaimer
